ArticleJAMA network open2021

Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials.

Chen Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.